FindTrial
Sign In

Comparison the effect of Gonadotropin releasing hormone agonist administration versus vaginal Progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility

Comparison the effect of Gonadotropin releasing hormone agonist administration versus vaginal Progesterone on serum progesterone in luteal phase in ovarian hyperstimulation and intrauterine insemination cycles in unexplained infertility

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201205159762N1
Enrollment
242
Registered
2012-07-11
Start date
2012-06-09
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility. female infertility,unspecified

Interventions

Intervention 1: Group1:Clomiphene 100mg daily from 3rd day to 7th day of the menstrual cycle,Gonadotopin(75 IU IM) injection 7th and 8th day , Human chorionic gonadotropin (10000 IU IM) will be a
Treatment - Drugs
Group1:Clomiphene 100mg daily from 3rd day to 7th day of the menstrual cycle,Gonadotopin(75 IU IM) injection 7th and 8th day , Human chorionic gonadotropin (10000 IU IM) will be administered when
Group2: Clomiphene 100mg daily from 3rd day to 7th day of the menstrual cycle,Gonadotopin(75 IU IM) injection 7th and 8th day , Human chorionic gonadotropin (10000 IU IM) will be administered when dom

Sponsors

Vice-chancellor for research of Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
17 Years to 39 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age10ng/ml in previous cycles exclusion criteria: previous ovarian surgery; Single ovary; polycystic ovaries on ultrasound examination; hypogonadotropic hypogonadism

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Serum progesterone in luteal phase. Timepoint: 10 days after intra uterine insemination. Method of measurement: blood sampling-ng/ml.—

Secondary

MeasureTime frame
Pregnancy. Timepoint: 14 days after intra uterine insemination. Method of measurement: blood sampling-iu/ml.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJaleh Mohamadpoor

Tehran University of Medical Sciences

mohamadpoorjaleh@yahoo.com+98 21 8890 0002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026